News: Latest News

Tempero Bio Secures $70 Million Series B Financing to Advance TMP-301 into Phase 2 Trials for Substance Use Disorders

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug

Tempero Bio Announces FDA Clearance

Aditum announces CEO for Ancora Bio

Aditum Bio announces Ancora Bio

$133 Million to Play the Startup Game - Aditum Bio

Aditum Bio launches its second startup: Tempero Bio

Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders

Lilly Completes Acquisition of Versanis Bio for $1.925 Billion

EmbarkNeuro Announces Initiation of Phase 2 Trial

Via Nova Therapeutics Announces $20 Million Series A Financing

Aditum Bio announces Anteris Bio

Novartis alums Jimenez, Fishman unveil their next act

Sosei allies with ex-Novartis team

Aditum Bio Announces Formation of Celexor Bio

Aditum Bio Announces Formation of Vitalli Bio

Aditum Bio Announces Formation of Motric Bio

Versanis Bio Announces $70 million Series A Financing

Tempero Bio is launched

Aditum Bio launches its second company: Tempero Bio